A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2018
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 12 Sep 2017 As of 2nd May 2017, 3 eligible patients have been enrolled, according to trial design presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 14 Feb 2017 New trial record